Citations (25)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Atike Bahcivan, Mehmet Gamsizkan, Sinem Kantarcioglu Coskun, Sengul Cangur, Alpaslan Yuksel, Aysegul Ceyhan & Binnur Onal. (2020) KRAS, BRAF, PIK3CA mutation frequency of radical prostatectomy samples and review of the literature. The Aging Male 23:5, pages 1627-1641.
Read now
Read now
Articles from other publishers (24)
Vivek Subbiah, Robert J. Kreitman, Zev A. Wainberg, Anas Gazzah, Ulrik Lassen, Alexander Stein, Patrick Y. Wen, Sascha Dietrich, Maja J. A. de Jonge, Jean-Yves Blay, Antoine Italiano, Kan Yonemori, Daniel C. Cho, Filip Y. F. L. de Vos, Philippe Moreau, Elena Elez Fernandez, Jan H. M. Schellens, Christoph C. Zielinski, Suman Redhu, Aislyn Boran, Vanessa Q. Passos, Palanichamy Ilankumaran & Yung-Jue Bang. (2023) Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial. Nature Medicine 29:5, pages 1103-1112.
Crossref
Crossref
Fabio Catalano, Malvina Cremante, Bruna Dalmasso, Chiara Pirrone, Agostina Lagodin D’Amato, Massimiliano Grassi & Danila Comandini. (2023) Molecular Tailored Therapeutic Options for Advanced Gastrointestinal Stromal Tumors (GISTs): Current Practice and Future Perspectives. Cancers 15:7, pages 2074.
Crossref
Crossref
Mojca Unk, Barbara Jezeršek Novaković & Srdjan Novaković. (2023) Molecular Mechanisms of Gastrointestinal Stromal Tumors and Their Impact on Systemic Therapy Decision. Cancers 15:5, pages 1498.
Crossref
Crossref
Dominic J. Lambo, Charlotta G. Lebedenko, Paige A. McCallum & Ipsita A. Banerjee. (2022) Molecular dynamics, MMGBSA, and docking studies of natural products conjugated to tumor-targeted peptide for targeting BRAF V600E and MERTK receptors. Molecular Diversity 27:1, pages 389-423.
Crossref
Crossref
Zing Hong Eng, Mardiaty Iryani Abdullah, Khoon Leong Ng, Azlina Abdul Aziz, Nurul Hannis Arba’ie, Nurullainy Mat Rashid & Sarni Mat Junit. (2023) Whole-exome sequencing and bioinformatic analyses revealed differences in gene mutation profiles in papillary thyroid cancer patients with and without benign thyroid goitre background. Frontiers in Endocrinology 13.
Crossref
Crossref
Alfonso López de Sá, Alicia de Luna, Mónica Antoñanzas, Vanesa García-Barberán, Fernando Moreno-Anton & Jose A. García-Sáenz. (2022) Case report: Clinical success targeting BRAF-mutated, hormone receptor positive, HER2- negative advanced breast cancer patient with BRAF-inhibitor plus MEK- inhibitor. Frontiers in Oncology 12.
Crossref
Crossref
Seiiedeh Samaneh Taghian Jamaleddin Kolaii, Amir Reza Dehghanian & Marjan Jeddi. (2022) Concomitant uveal melanoma and papillary thyroid carcinoma: a case report. Journal of Medical Case Reports 16:1.
Crossref
Crossref
Tiane Chen, Jozef Malysz, Erik Washburn, Natthapol Songdej, Yong Zhang & Michael Bayerl. (2022) Mast cell leukemia with novel BRAF variant and concomitant atypical KIT variant. Cancer Genetics 266-267, pages 33-36.
Crossref
Crossref
Mona Foth & Martin McMahon. (2021) Autophagy Inhibition in BRAF-Driven Cancers. Cancers 13:14, pages 3498.
Crossref
Crossref
R. Danesi, S. Fogli, S. Indraccolo, M. Del Re, A.P. Dei Tos, L. Leoncini, L. Antonuzzo, L. Bonanno, V. Guarneri, A. Pierini, G. Amunni & P. Conte. (2021) Druggable targets meet oncogenic drivers: opportunities and limitations of target-based classification of tumors and the role of Molecular Tumor Boards. ESMO Open 6:2, pages 100040.
Crossref
Crossref
Briana R. Halle & Douglas B. Johnson. (2021) Defining and Targeting BRAF Mutations in Solid Tumors. Current Treatment Options in Oncology 22:4.
Crossref
Crossref
Ottavia Bernocchi, Marianna Sirico, Silvia Paola Corona, Carla Strina, Manuela Milani, Maria Rosa Cappelletti, Giuseppina Ferrero, Nicoletta Ziglioli, Valeria Cervoni, Andrea Macchiavelli, Giandomenico Roviello & Daniele Generali. (2021) Tumor Type Agnostic Therapy Carrying BRAF Mutation: Case Reports and Review of Literature. Pharmaceuticals 14:2, pages 159.
Crossref
Crossref
Pasquale Pisapia, Francesco Pepe, Antonino Iaccarino, Roberta Sgariglia, Mariantonia Nacchio, Gianluca Russo, Gianluca Gragnano, Umberto Malapelle & Giancarlo Troncone. (2020) BRAF: A Two-Faced Janus. Cells 9:12, pages 2549.
Crossref
Crossref
April K. S. Salama, Shuli Li, Erin R. Macrae, Jong-In Park, Edith P. Mitchell, James A. Zwiebel, Helen X. Chen, Robert J. Gray, Lisa M. McShane, Larry V. Rubinstein, David Patton, P. Mickey Williams, Stanley R. Hamilton, Deborah K. Armstrong, Barbara A. Conley, Carlos L. Arteaga, Lyndsay N. Harris, Peter J. O’Dwyer, Alice P. Chen & Keith T. Flaherty. (2020)
Dabrafenib and Trametinib in Patients With Tumors With
BRAF
V600E
Mutations: Results of the NCI-MATCH Trial Subprotocol H
. Journal of Clinical Oncology 38:33, pages 3895-3904.
Crossref
Crossref
Komal Srinivasa, Kevin A. Cross & Sonika Dahiya. (2020) BRAF Alteration in Central and Peripheral Nervous System Tumors. Frontiers in Oncology 10.
Crossref
Crossref
Vivek Subbiah, Christina Baik & John M. Kirkwood. (2020) Clinical Development of BRAF plus MEK Inhibitor Combinations. Trends in Cancer 6:9, pages 797-810.
Crossref
Crossref
Bao-Dong Qin, Xiao-Dong Jiao, Ke Liu, Ying Wu, Xi He, Jun Liu, Wen-Xing Qin, Zhan Wang & Yuan-Sheng Zang. (2019) Basket Trials for Intractable Cancer. Frontiers in Oncology 9.
Crossref
Crossref
Minny Bhatty, Shumei Kato, Sarina A. Piha‐Paul, Aung Naing, Vivek Subbiah, Helen J. Huang, Daniel D. Karp, Apostolia M. Tsimberidou, Ralph G. Zinner, Wen‐Jen Hwu, Milind Javle, Sapna P. Patel, Mimi I. Hu, Gauri R. Varadhachary, Anthony P. Conley, Nishma M. Ramzanali, Veronica R. Holley, Razelle Kurzrock, Funda Meric‐Bernstam, Young Kwang Chae, Kevin B. Kim, Gerald S. Falchook & Filip Janku. (2018)
Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with
BRAF
‐mutated melanoma and other advanced malignancies
. Cancer 125:3, pages 463-472.
Crossref
Crossref
Hyesun ParkMizuki Nishino, Jason L. HornickEric D. Jacobsen. (2019) Imaging of Histiocytosis in the Era of Genomic Medicine. RadioGraphics 39:1, pages 95-114.
Crossref
Crossref
Luis E. Raez & Edgardo S. Santos. (2018) Tumor Type-Agnostic Treatment and the Future of Cancer Therapy. Targeted Oncology 13:5, pages 541-544.
Crossref
Crossref
Claudia Omarini, Maria Elisabetta Filieri, Stefania Bettelli, Samantha Manfredini, Shaniko Kaleci, Cecilia Caprera, Cecilia Nasso, Monica Barbolini, Giorgia Guaitoli, Luca Moscetti, Antonino Maiorana, Pier Franco Conte, Stefano Cascinu & Federico Piacentini. (2018) Mutational Profile of Metastatic Breast Cancer Tissue in Patients Treated with Exemestane Plus Everolimus. BioMed Research International 2018, pages 1-8.
Crossref
Crossref
Maria Rita Gaiser, Nikolas von Bubnoff, Christoffer Gebhardt & Jochen Sven Utikal. (2018) Liquid Biopsy zur Überwachung von Melanompatienten. JDDG: Journal der Deutschen Dermatologischen Gesellschaft 16:4, pages 405-416.
Crossref
Crossref
Maria Rita Gaiser, Nikolas von Bubnoff, Christoffer Gebhardt & Jochen Sven Utikal. (2018) Liquid biopsy to monitor melanoma patients. JDDG: Journal der Deutschen Dermatologischen Gesellschaft 16:4, pages 405-414.
Crossref
Crossref
Ting Xie, Chun‐Yu Huang, Xu Kang, Jia‐Sheng Luo, Xiao‐Min Qin & Feng Han. (2017) A Network Meta‐Analysis of Short and Long‐Term Efficacy of Targeted Therapy With Single or Double‐Drug Regimens in the Treatment of Stage III/IV Malignant Melanoma Based on 16 Randomized Controlled Trials. Journal of Cellular Biochemistry 119:1, pages 640-649.
Crossref
Crossref